Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

Stock Information for Avant Technologies Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avant Technologies Inc

Absci Announces First Participants Dosed in Phase 1/2a HEADLINE(TM) Trial of AI-Designed Antibody ABS-201(TM) for Androgenetic Alopecia
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
Absci to Participate in Upcoming Investor Conferences
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
Absci Announces Pricing of Public Offering of Common Stock

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.